Table 3.
Duration of follow-up Initial cohort | Age years | Number at risk | Cases of resolution | Rate of resolution for follow-up period (95% CI) |
---|---|---|---|---|
6 months | ||||
HMB | 40–44 | 670 | 116 | 17.3% (14.6–20.4%) |
45–49 | 670 | 109 | 16.3% (13.7–19.3%) | |
50–54 | 302 | 106 | 35.1% (30.0–40.8%) | |
HMB with heaviness that interferes with life | 40–44 | 227 | 16 | 7.0% (4.4–11.1%) |
45–49 | 251 | 20 | 8.0% (5.8–13.2%) | |
50–54 | 109 | 32 | 29.4% (21.6–38.5%) | |
1 year | ||||
HMB | 40–44 | 577 | 55 | 9.5% (7.4–12.2%) |
45–49 | 554 | 51 | 9.2% (7.1–11.9%) | |
50–54 | 260 | 71 | 27.3% (22.3–33.0%) | |
HMB with heaviness that interferes with life | 40–44 | 184 | 6 | 3.3% (1.5–6.9%) |
45–49 | 206 | 11 | 5.3% (3.0–9.3%) | |
50–54 | 89 | 20 | 22.5% (15.0–32.2%) | |
2 years | ||||
HMB | 40–44 | 258 | 10 | 3.9% (2.1–7.0%) |
45–49 | 248 | 20 | 8.1% (5.3–12.1%) | |
50–54 | 126 | 32 | 25.4% (18.6–33.7%) | |
HMB with heaviness that interferes with life | 40–44 | 77 | 2 | 2.6% (0.7–9.0%) |
45–49 | 88 | 7 | 8.0% (3.9–15.5%) | |
50–54 | 43 | 9 | 20.9% (11.4–35.2%) |